

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Yoshinaga, Steven K. Confirmation No.: 4100
Serial No.: 09/728,421 Group Art Unit No.: 1644
Filed: November 28, 2000 Examiner: Gambel, Phillip
Title: Polypeptides Involved in Immune Response
Docket No.: A-579-US-CNT

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Examiner:

As a means of complying with the duty of disclosure under 37 C.F.R. §§ 1.56, applicant(s) submit(s) a "List of References Cited by Applicant" or an "Information Disclosure Statement by Applicant" and provide(s) a copy of each listed item of information that is not a U.S. Patent or published U.S. Patent Application for consideration by the Examiner.

Applicant(s) make(s) no determination of relevancy with respect to the item(s) of information submitted herewith and request(s) that the Examiner make an independent determination of relevance and/or materiality of the item(s) of information.

Identification of the listed item(s) of information is not to be construed as an admission by applicant(s) or attorney for applicant(s) that such item(s) of information are available or qualify as "prior art" against the subject application. Applicant(s) reserve(s) the right to remove any item of information which the Patent and Trademark Office may cite against the subject application.

CERTIFICATE OF EFS-WEB TRANSMISSION

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted electronically through EFS-WEB to the Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450, on the date appearing below.

February 14, 2012

Date

/Michele I. Peña/

Signature

SUBMISSION UNDER 37 C.F.R § 1.97(b)



In accordance with 37 C.F.R. § 1.97(b), the information disclosure statement submitted herewith is being filed within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d), or within three months of the date of entry of the national stage as set forth in § 1.491 in an international application, or before the mailing of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under § 1.114.

Because the information disclosure statement is being submitted in compliance with 37 C.F.R. § 1.97(b), no statement under 37 C.F.R. § 1.97(e) is required and no fee under § 1.17(p) is due.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519.

Please send all future correspondence to:

Respectfully submitted,

/Robert B. Winter/

CUSTOMER NO: 21069

US Patent Operations / RBW
Amgen Inc.
One Amgen Center Drive / MS 28-2-C
Thousand Oaks, California 91320-1799

Robert B. Winter
Attorney/Agent for Applicant(s)
Registration No.: 34,458
Phone: (805) 447-2425
Date: February 14, 2012